![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and pharmacokinetics of ABI-H3733, a
novel second-generation HBV core inhibitor:
Results from a Phase 1a study in healthy volunteers
|
|
|
AASLD 2021 Nov 12-15
Edward Gane1, Christian Schwabe2, Katia Alves3, Marc Evanchik3, Julie Ma4, Katie Zomorodi4, Steven J Knox4, Luisa M Stamm4
1Liver Transplant Unit, University of Auckland, Auckland, New Zealand; 2New Zealand Clinical Research, New Zealand; 3Former employee of Assembly Biosciences, Inc.; 4Assembly Biosciences, Inc., South San Francisco, CA, USA
![1214211](../images/121421/121421-5/1214211.gif)
![1214212](../images/121421/121421-5/1214212.gif)
![1214213](../images/121421/121421-5/1214213.gif)
![1214214](../images/121421/121421-5/1214214.gif)
![1214215](../images/121421/121421-5/1214215.gif)
![1214216](../images/121421/121421-5/1214216.gif)
![1214217](../images/121421/121421-5/1214217.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|